Summary

Persistence Market Research has recently released a comprehensive report on the global market for dermatology biologics, offering a thorough evaluation of key market dynamics, including drivers, trends, opportunities, and challenges. This detailed analysis provides valuable insights into the market structure.

Key Insights:

• Dermatology Biologics Market Size (2024E): USD 6.011 Billion
• Projected Market Value (2032F): USD 10.175 Billion
• Global Market Growth Rate (CAGR 2024 to 2032): 6.8%

Dermatology Biologics Market - Report Scope:

Dermatology biologics are crucial in treating various chronic skin conditions, such as psoriasis, atopic dermatitis, and hidradenitis suppurativa. Derived from living cells, these biologics offer targeted therapies that modulate the immune response, providing relief for patients with moderate to severe skin disorders. The dermatology biologics market serves hospitals, specialty clinics, and homecare settings, offering a range of biologic therapies including monoclonal antibodies and fusion proteins.

Market Growth Drivers:

Several factors drive the growth of the global dermatology biologics market. Increasing awareness of biologics as effective treatments for chronic dermatological conditions like psoriasis and eczema contributes significantly to market expansion. The rising prevalence of these skin disorders and the demand for long-term therapeutic solutions are key growth drivers. Technological advancements in biologic drug development, such as the introduction of biosimilars and next-generation biologics, enhance treatment outcomes and minimize adverse effects, further stimulating market growth. Additionally, the growing adoption of home-based biologic therapies and the expansion of telemedicine services open new avenues for market players to reach a broader patient base.

Market Restraints:

Despite its promising growth prospects, the dermatology biologics market faces challenges including high treatment costs, stringent regulatory approval processes, and limited accessibility in low- and middle-income regions. The complex manufacturing processes and strict regulations governing biologics development impose significant cost burdens on manufacturers, impacting market pricing and patient access. The high cost of biologic treatments presents barriers to market penetration, particularly in regions with constrained healthcare budgets. Overcoming these economic and regulatory barriers will require collaboration between industry stakeholders, policymakers, and healthcare providers to promote affordable and accessible biologic therapies.

Market Opportunities:

The dermatology biologics market presents substantial growth opportunities driven by ongoing research and development, increased healthcare expenditure, and evolving patient care models. The introduction of personalized biologic therapies, tailored to individual patient needs, enhances treatment efficacy and reduces side effects, expanding market potential. The development of biosimilars and the focus on cost-effective treatment options offer additional opportunities for market players to address a larger patient base. Strategic partnerships, investment in research and development, and the integration of digital health technologies, such as remote monitoring and telemedicine platforms, are essential to capitalize on emerging opportunities and maintain market leadership in the dynamic dermatology biologics landscape.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the global dermatology biologics market?
• Which biologic therapies and applications are leading the adoption of dermatology biologics across various healthcare settings?
• How are technological advancements reshaping the competitive landscape of the dermatology biologics market?
• Who are the key players in the dermatology biologics market, and what strategies are they employing to stay relevant?
• What are the emerging trends and future prospects in the global dermatology biologics market?

Competitive Intelligence and Business Strategy:

Leading companies in the global dermatology biologics market, such as AbbVie Inc., Amgen Inc., and Johnson & Johnson, are focusing on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in research and development to create advanced biologic therapies, including monoclonal antibodies and fusion proteins, to meet diverse patient needs and clinical requirements. Collaborations with healthcare providers, research institutions, and regulatory agencies facilitate market access and promote technology adoption. Additionally, a focus on clinical research, real-world evidence generation, and patient education supports market growth and improves patient outcomes in the evolving dermatology biologics landscape.

Key Companies Profiled:

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• UCB S.A.
• Regeneron Pharmaceuticals, Inc.
• Sanofi S.A.

Key Segments Covered in Dermatology Biologics Industry Research

Dermatology Biologics Market by Product Type:
• Interleukin Inhibitors
• Tumor Necrosis Factor Inhibitors

Dermatology Biologics Market by End User:
• Hospital Pharmacies
• Retail Pharmacies
• e-Commerce

Dermatology Biologics Market by Region:
• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• The Middle East & Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions & Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Development Trends
4. Key Success Factors
4.1. Key Regulation
4.2. Disease Epidemiology
4.3. Patient Treatment Journey
4.4. Pipeline Assessment
4.5. PESTLE Analysis
4.6. Porters Analysis
4.7. Value Chain Analysis
4.8. Key Promotion Strategies, by Manufacturers
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure Outlook
5.1.3. Global Dermatology Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Patient Awareness related Initiatives
5.2.2. Increasing Prevalence of Skin Disorder
5.2.3. Growing R&D in Healthcare Sector
5.2.4. Per Patient spending
5.2.5. Increasing Number of Acquisitions in the Key Regions
5.2.6. Rising Collaboration among Key Players
5.2.7. Rising Demand for Biologicals
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Product Type
6.1.2. Revenue By End User
6.1.3. Revenue By Region
6.2. 2024 Market Scenario
7. Global Dermatology Biologics Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2032
7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Dermatology Biologics Market Analysis 2019-2023 and Forecast 2024-2032, By Product Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Product Type, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Product Type, 2024-2032
8.3.1. Interleukin Inhibitors
8.3.2. Tumor Necrosis Factor Inhibitor
8.4. Market Attractiveness Analysis By Product Type
9. Global Dermatology Biologics Market Analysis 2019-2023 and Forecast 2024-2032, By End User
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis By End User, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By End User, 2024-2032
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. E-Commerce
9.4. Market Attractiveness Analysis By End User
10. Global Dermatology Biologics Market Analysis 2019-2023 and Forecast 2024-2032, by Region
10.1. Introduction
10.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. East Asia
10.3.5. South Asia
10.3.6. Oceania
10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Dermatology Biologics Market Analysis 2019-2023 and Forecast 2024-2032
11.1. Introduction
11.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2032
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Product Type
11.3.3. By End User
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Product Type
11.4.3. By End User
11.5. Market Trends
11.6. Key Market Participants - Intensity Mapping
11.7. Drivers and Restraints - Impact Analysis
11.8. Country Level Analysis & Forecast
11.8.1. U.S. Dermatology Biologics Market
11.8.1.1. Introduction
11.8.1.2. Market Analysis and Forecast by Market Taxonomy
11.8.1.2.1. By Product Type
11.8.1.2.2. By End User
11.8.2. Canada Dermatology Biologics Market
11.8.2.1. Introduction
11.8.2.2. Market Analysis and Forecast by Market Taxonomy
11.8.2.2.1. By Product Type
11.8.2.2.2. By End User
12. Latin America Dermatology Biologics Market Analysis 2019-2023 and Forecast 2024-2032
12.1. Introduction
12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2032
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Argentina
12.3.1.3. Mexico
12.3.1.4. Rest of Latin America
12.3.2. By Product Type
12.3.3. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Product Type
12.4.3. By End User
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country Level Analysis & Forecast
12.8.1. Brazil Dermatology Biologics Market
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Product Type
12.8.1.2.2. By End User
12.8.2. Argentina Dermatology Biologics Market
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Product Type
12.8.2.2.2. By End User
12.8.3. Mexico Dermatology Biologics Market
12.8.3.1. Introduction
12.8.3.2. Market Analysis and Forecast by Market Taxonomy
12.8.3.2.1. By Product Type
12.8.3.2.2. By End User
13. Europe Dermatology Biologics Market Analysis 2019-2023 and Forecast 2024-2032
13.1. Introduction
13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2032
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. France
13.3.1.3. Italy
13.3.1.4. Spain
13.3.1.5. UK
13.3.1.6. BENELUX
13.3.1.7. Russia
13.3.1.8. Nordic Countries
13.3.1.9. Rest of Europe
13.3.2. By Product Type
13.3.3. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Product Type
13.4.3. By End User
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. Germany Dermatology Biologics Market
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Product Type
13.8.1.2.2. By End User
13.8.2. France Dermatology Biologics Market
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Product Type
13.8.2.2.2. By End User
13.8.3. Italy Dermatology Biologics Market
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Product Type
13.8.3.2.2. By End User
13.8.4. Spain Dermatology Biologics Market
13.8.4.1. Introduction
13.8.4.2. Market Analysis and Forecast by Market Taxonomy
13.8.4.2.1. By Product Type
13.8.4.2.2. By End User
13.8.5. U.K. Dermatology Biologics Market
13.8.5.1. Introduction
13.8.5.2. Market Analysis and Forecast by Market Taxonomy
13.8.5.2.1. By Product Type
13.8.5.2.2. By End User
13.8.6. Benelux Union Dermatology Biologics Market
13.8.6.1. Introduction
13.8.6.2. Market Analysis and Forecast by Market Taxonomy
13.8.6.2.1. By Product Type
13.8.6.2.2. By End User
13.8.7. Nordic Countries Dermatology Biologics Market
13.8.7.1. Introduction
13.8.7.2. Market Analysis and Forecast by Market Taxonomy
13.8.7.2.1. By Product Type
13.8.7.2.2. By End User
13.8.8. Russia Dermatology Biologics Market
13.8.8.1. Introduction
13.8.8.2. Market Analysis and Forecast by Market Taxonomy
13.8.8.2.1. By Product Type
13.8.8.2.2. By End User
14. South Asia and Pacific Dermatology Biologics Market Analysis 2019-2023 and Forecast 2024-2032
14.1. Introduction
14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2032
14.3.1. By Country
14.3.1.1. India
14.3.1.2. Indonesia
14.3.1.3. Malaysia
14.3.1.4. Thailand
14.3.1.5. Rest of South Asia
14.3.2. By Product Type
14.3.3. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Product Type
14.4.3. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. India Dermatology Biologics Market
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Product Type
14.8.1.2.2. By End User
14.8.2. Indonesia Dermatology Biologics Market
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Product Type
14.8.2.2.2. By End User
14.8.3. Malaysia Dermatology Biologics Market
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Product Type
14.8.3.2.2. By End User
14.8.4. Thailand Dermatology Biologics Market
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Product Type
14.8.4.2.2. By End User
15. East Asia Dermatology Biologics Market Analysis 2019-2023 and Forecast 2024-2032
15.1. Introduction
15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2032
15.3.1. By Country
15.3.1.1. China
15.3.1.2. Japan
15.3.1.3. South Korea
15.3.2. By Product Type
15.3.3. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Product Type
15.4.3. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. China Dermatology Biologics Market
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Product Type
15.8.1.2.2. By End User
15.8.2. Japan Dermatology Biologics Market
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Product Type
15.8.2.2.2. By End User
15.8.3. South Korea Dermatology Biologics Market
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Product Type
15.8.3.2.2. By End User
16. Oceania Dermatology Biologics Market Analysis 2019-2023 and Forecast 2024-2032
16.1. Introduction
16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2032
16.3.1. By Country
16.3.1.1. Australia
16.3.1.2. New Zealand
16.3.2. By Product Type
16.3.3. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Product Type
16.4.3. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. Australia Dermatology Biologics Market
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Product Type
16.8.1.2.2. By End User
16.8.2. New Zealand Dermatology Biologics Market
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Product Type
16.8.2.2.2. By End User
17. Middle East and Africa Dermatology Biologics Market Analysis 2019-2023 and Forecast 2024-2032
17.1. Introduction
17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Market Taxonomy, 2024-2032
17.3.1. By Country
17.3.1.1. Turkey
17.3.1.2. Israel
17.3.1.3. South Africa
17.3.1.4. Rest of Middle East and Africa
17.3.2. By Product Type
17.3.3. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Product Type
17.4.3. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. Turkey Dermatology Biologics Market
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Product Type
17.8.1.2.2. By End User
17.8.2. Israel Dermatology Biologics Market
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Product Type
17.8.2.2.2. By End User
17.8.3. South Africa Dermatology Biologics Market
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Product Type
17.8.3.2.2. By End User
18. Market Structure Analysis
18.1. Market Analysis by Tier of Companies
18.2. Market Share Analysis of Top Players
18.3. Market Presence Analysis
18.3.1. Regional Footprint by Players
18.3.2. Product Type Footprint by Players
18.3.3. Channel Footprint by Players
19. Competition Analysis
19.1. Competition Dashboard
19.2. Competition Benchmarking
19.3. Competition Deep Dive
19.3.1. Merck and Co. Inc.
19.3.1.1. Overview
19.3.1.2. Product Type Portfolio
19.3.1.3. Key Financials
19.3.1.4. SWOT Analysis
19.3.1.5. Key Developments
19.3.1.6. Sales Footprint
19.3.1.7. Strategy Overview
19.3.1.7.1. Marketing Strategy
19.3.1.7.2. Product Type Strategy
19.3.1.7.3. Channel Strategy
19.3.2. Novartis AG
19.3.2.1. Overview
19.3.2.2. Product Type Portfolio
19.3.2.3. Key Financials
19.3.2.4. SWOT Analysis
19.3.2.5. Key Developments
19.3.2.6. Sales Footprint
19.3.2.7. Strategy Overview
19.3.2.7.1. Marketing Strategy
19.3.2.7.2. Product Type Strategy
19.3.2.7.3. Channel Strategy
19.3.3. Pfizer Inc.
19.3.3.1. Overview
19.3.3.2. Product Type Portfolio
19.3.3.3. Key Financials
19.3.3.4. SWOT Analysis
19.3.3.5. Key Developments
19.3.3.6. Sales Footprint
19.3.3.7. Strategy Overview
19.3.3.7.1. Marketing Strategy
19.3.3.7.2. Product Type Strategy
19.3.3.7.3. Channel Strategy
19.3.4. AbbVie Inc.
19.3.4.1. Overview
19.3.4.2. Product Type Portfolio
19.3.4.3. Key Financials
19.3.4.4. SWOT Analysis
19.3.4.5. Key Developments
19.3.4.6. Sales Footprint
19.3.4.7. Strategy Overview
19.3.4.7.1. Marketing Strategy
19.3.4.7.2. Product Type Strategy
19.3.4.7.3. Channel Strategy
19.3.5. Amgen Inc.
19.3.5.1. Overview
19.3.5.2. Product Type Portfolio
19.3.5.3. Key Financials
19.3.5.4. SWOT Analysis
19.3.5.5. Key Developments
19.3.5.6. Sales Footprint
19.3.5.7. Strategy Overview
19.3.5.7.1. Marketing Strategy
19.3.5.7.2. Product Type Strategy
19.3.5.7.3. Channel Strategy
19.3.6. AstraZenca
19.3.6.1. Overview
19.3.6.2. Product Type Portfolio
19.3.6.3. Key Financials
19.3.6.4. SWOT Analysis
19.3.6.5. Key Developments
19.3.6.6. Sales Footprint
19.3.6.7. Strategy Overview
19.3.6.7.1. Marketing Strategy
19.3.6.7.2. Product Type Strategy
19.3.6.7.3. Channel Strategy
19.3.7. Celgene Corporation
19.3.7.1. Overview
19.3.7.2. Product Type Portfolio
19.3.7.3. Key Financials
19.3.7.4. SWOT Analysis
19.3.7.5. Key Developments
19.3.7.6. Sales Footprint
19.3.7.7. Strategy Overview
19.3.7.7.1. Marketing Strategy
19.3.7.7.2. Product Type Strategy
19.3.7.7.3. Channel Strategy
19.3.8. Eli Lilly and Company
19.3.8.1. Overview
19.3.8.2. Product Type Portfolio
19.3.8.3. Key Financials
19.3.8.4. SWOT Analysis
19.3.8.5. Key Developments
19.3.8.6. Sales Footprint
19.3.8.7. Strategy Overview
19.3.8.7.1. Marketing Strategy
19.3.8.7.2. Product Type Strategy
19.3.8.7.3. Channel Strategy
19.3.9. Johnson and Johnson (Janssen Biotech Inc.)
19.3.9.1. Overview
19.3.9.2. Product Type Portfolio
19.3.9.3. Key Financials
19.3.9.4. SWOT Analysis
19.3.9.5. Key Developments
19.3.9.6. Sales Footprint
19.3.9.7. Strategy Overview
19.3.9.7.1. Marketing Strategy
19.3.9.7.2. Product Type Strategy
19.3.9.7.3. Channel Strategy
20. Assumptions and Acronyms Used
21. Research Methodology